Sandoz Opens New Development Center in Ljubljana, Slovenia
Ljubljana, Slovenia – Sandoz, a leading global manufacturer of generic and similar biological drugs, has inaugurated a significant new development center in Slovenia, marking the first phase of a comprehensive expansion strategy. According to Gregor Makuc, CEO and President of Sandoz Slovenia, this initiative establishes a complete chain encompassing development and production within the field of similar biological drugs. The facility, located within a 10,000 square meter space, is intended to become Sandoz’s primary center for development activities.
Makuc highlighted the importance of the center’s success, stating, “This facility is not inspiring only because of its structure, high technology or process improvements. It is important because of knowledge, because of development capabilities and, above all, because of the people.”
More than 200 scientists and researchers will operate from the new center. The construction of the building represents a key investment by Sandoz within Slovenia.
This expansion underscores the company’s commitment to innovation and its strategic focus on leveraging Slovenian expertise in the development of similar biological drugs. The project represents a substantial step in Sandoz’s global operations, solidifying Slovenia’s role as a vital hub for the company’s research and development efforts.
Topics: #sandoz #slovenia #development
This investment in Slovenia demonstrates Sandoz’s commitment to advancing biological drug development.